COMPARE · Reviewed July 29, 2026
AVGO vs NVDA
Verdict: Side-by-side breakdown using the Bull Rankings model. AVGO scored 73.3, NVDA scored 86.6 — NVDA leads.
Compare another set
AVGO
Broadcom Inc.
73.3
$370.32 · $1.8T
fundamentals as of
Score gap
13.3
NVDA leads
NVDA
NVIDIA Corporation
86.6
$190.01 · $4.6T
fundamentals as of
The model, pillar by pillar (0–100 each)
AVGO
stronger →← stronger
NVDA
80
Qualityreturns · margins · balance sheet
88
100
Growthrevenue & earnings expansion
100
49
Valuevaluation vs sector peers
74
NVDA is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AVGO
NVDA
$32.8bA
FCF
$119.1bA
+32.3%A
Rev
+70.7%A
0.74C+
D/E
0.07A-
61.5xC
P/E
29.1xB
0.43A
PEG
0.54A-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
AVGO
NVDA
215% above
Price vs fair valuelower is cheaper
187% above
~47%/yr
Growth the price implies10-yr FCF · lower = less priced in
~46%/yr
-76%
1-yr DCF upside
-73%
-68%
5-yr DCF upside
-65%
-54%
10-yr DCF upside
-51%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AVGO
Why this score
- Raising its dividend
NVDA
Why this score
- Raising its dividend
- Durable high returns
The companies
AVGOBroadcom Inc.
Why now
Semiconductors · market cap $1.8T. Down 25% from 52-week high of $495.00 — deep drawdown territory. Revenue growing +32% — in hypergrowth territory. PEG 0.43 — paying under fair value for the growth rate. 45 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $527.00 (implying +42% upside).
Moat
Net margin 39% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 33% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 112% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 61.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Beta 1.46 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. P/S 23.3x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
NVDANVIDIA Corporation
Why now
Semiconductors · market cap $4.6T. 20% off the 52-week high of $236.54. Revenue growing +71% — in hypergrowth territory. PEG 0.54 — paying under fair value for the growth rate. 58 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $302.83 (implying +59% upside).
Moat
Net margin 63% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 82% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $4.6T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Beta 2.21 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. P/S 18.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Semiconductor cyclicality — inventory corrections compress margins faster than analysts model. Monitor channel inventory and book-to-bill ratios as leading indicators.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.